Lower IVC doses tend to be used for patients with severe infection with the proposed mechanism of IVC being primarily support of organ and immune function. Intravenous administration may also be required to enhance diffusion of vitamin C into solid tumours with subsequent modulation of important cell signaling pathways. One of the proposed mechanisms of IVC is to target cancer cells via an indirect pro-oxidant mechanism relying on transition metal ion-dependent generation of hydrogen peroxide vitamin C must be injected intravenously in order to achieve sufficiently high plasma vitamin C concentrations to facilitate this mechanism. Pharmacokinetic studies have found that the peak concentration of vitamin C achievable in blood plasma following oral ingestion is about 220 μmol/L, whereas at least 15 mmol/L is achievable following IVC administration. Furthermore, recent studies indicate that IVC can improve the outcomes of patients with severe infections and burns, and improve post-surgical recovery. IVC has been shown to be effective at decreasing common cancer-related symptoms and chemotherapy side-effects, thus improving overall patient quality of life. Intravenous vitamin C (IVC) has been used for many decades by health care practitioners for a number of indications, particularly cancer and infection. Although not the primary focus of this study, it was also observed that there was no significant change in mean serum creatinine or eGFR for those who had follow-up renal function blood tests. In conclusion, IVC therapy was not associated with patient-reported renal stones. In addition, the majority of patients investigated had stable renal function during the study period as evidenced by little change in serum creatinine levels and estimated glomerular filtration rate (eGFR) following IVC. No renal stones were reported by any patients in the study, despite 8% of the patients having a history of renal stones. Inquiries into the occurrence of renal stones were conducted at enrolment, 6 and 12 months, and renal function blood tests were conducted at enrolment, 4 weeks and every 12 weeks thereafter in a subgroup of patients. We carried out a prospective case series study of 157 adult patients who commenced IVC therapy at Integrated Health Options clinic between 1 September 2011 and 31 August 2012, with follow-up for 12 months. Our aim was to measure the frequency of reported renal stones in patients receiving IVC therapy. ![]() A few cases associating high dose intravenous vitamin C (IVC) administration with renal stone formation have been reported in the literature, however, no long-term studies investigating IVC administration and reported renal stones have been carried out.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |